ECLIPSE: Adaptable Model Predictive Control on a Chip for Personalized and Point-of-Care Plasma Medicine

生物医学设备在医疗诊断和治疗中变得越来越普遍，其中即时医疗设备在个性化医疗方面显示出巨大的前景。尽管如此，医疗治疗和设备的日益复杂性需要开发先进的决策和自动控制系统，以确保生物医学设备的安全，可预测和治疗有效的操作。为此，该项目的重点是利用低温等离子体生物医学设备的医疗潜力。一些最有前途的等离子体医学应用包括治疗生物膜相关感染、治疗伤口和皮肤病、辅助癌症治疗、治疗病毒感染和生物植入物的表面改性。该项目旨在利用机器学习和基于优化的控制的进步，开发智能决策系统，用于使用床旁等离子生物医学设备为个体受试者提供个性化的等离子剂量输送。智能决策系统可以通过安全和（治疗）有效地控制用于使用点等离子体医学和生物技术应用的等离子体设备来创造前所未有的机会，例如，在资源有限的社区。这项研究的结果将被用于一个新的研究生课程学习为基础的控制，PI将与伯克利分校的工程师和导师计划，指导本科生进行高中水平的科学lesions.Despite最近的进展模型预测控制（MPC）的等离子体生物医学设备，但仍然存在对个性化和即时等离子体生物医学应用的重要挑战。该项目旨在开发一个系统理论框架，用于MPC片上控制器的优化设计和数据高效适应，以使用即时医疗生物医学设备对复杂接口进行安全和个性化的等离子体治疗。这一目标将通过以下方式实现：（1）开发用于具有快速动态的不确定非线性系统的片上MPC的软件和硬件协同设计的多目标优化框架（即，kHz采样率）;（2）开发贝叶斯优化方法，用于安全和最佳性能导向的片上MPC适配，其特别适合于控制策略适配的性能数据稀缺的应用;以及（3）实验性地展示具有用于细菌消毒的原型生物医学应用的冷大气等离子体射流的片上MPC的自适应性。该项目的系统理论发展的影响将超越等离子体，并可以转化为其他技术系统，其中自适应MPC片上控制器可以发挥关键作用。该项目还提供计算基准和开源代码，以提供对最先进技术所取得的改进的可衡量的演示。该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估来支持。

Biomedical devices are becoming increasingly ubiquitous for medical diagnosis and therapies, wherein point-of-care devices have shown great promise for personalized medicine. Nonetheless, the increasing complexity of medical therapeutics and devices necessitates the development of advanced decision-making and automatic control systems to ensure safe, predictable, and therapeutically effective operation of biomedical devices. To this end, this project focuses on harnessing the medical potential of low-temperature plasma biomedical devices. Some of the most promising plasma medicine applications include treatment of biofilm-related infections, treatment of wounds and skin diseases, assistance in cancer treatment, treatment of virus infections, and surface modification of bioimplants. This project aims to leverage advances in machine learning and optimization-based control to develop intelligent decision-making systems for personalizing plasma dose delivery for individual subjects using point-of-care plasma biomedical devices. Intelligent decision-making systems can create unprecedented opportunities by enabling safe and (therapeutically) effective control of plasma devices for point-of-use plasma medicine and biotechnology applications, for example, in resource-limited communities. The results of this research will be used in a new graduate course on learning-based control, and the PI will partner with the Berkeley Engineers and Mentors program to mentor undergraduate students in conducting high school level science lessons.Despite recent advances in model predictive control (MPC) of plasma biomedical devices, there yet remains important challenges towards personalized and point-of-care plasma biomedical applications. This project aims to develop a systems-theoretic framework for optimal design and data-efficient adaptation of MPC-on-a-chip controllers for safe and personalized plasma treatment of complex interfaces using point-of-care biomedical devices. This objective will be realized through: (1) developing a multi-objective optimization framework for co-design of software and hardware for MPC-on-a-chip for uncertain nonlinear systems with fast dynamics (i.e., kHz sampling rates); (2) developing Bayesian optimization methods for safe and optimal performance-oriented adaptation of MPC-on-a-chip that is especially suited for applications in which performance data for control policy adaptation are scarce; and (3) experimentally demonstrating adaptive MPC-on-a-chip of a cold atmospheric plasma jet with prototypical biomedical applications for bacterial disinfection. The impact of the systems-theoretic developments of this project will be beyond plasmas and can translate to other technical systems in which adaptive MPC-on-a-chip controllers can play a critical role. The project also delivers computational benchmarks and open-source codes to provide a measurable demonstration of the improvements achieved over the state-of-the-art.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.